Leisure Capital Management Nektar Therapeutics Transaction History

Leisure Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $141,347 - $263,139	-4,645 Closed	0 $0
Q3 2018 Nov 09, 2018	SELL	$46.46 - $68.49 $23,322 - $34,381	-502 Reduced 9.75%	4,645 $283,000
Q2 2018 Aug 02, 2018	BUY	$46.25 - $104.45 $20,257 - $45,749	438 Added 9.3%	5,147 $251,000
Q1 2018 May 11, 2018	SELL	$57.4 - $108.44 $279,710 - $528,428	-4,873 Reduced 50.86%	4,709 $500,000
Q4 2017 Feb 12, 2018	SELL	$23.02 - $60.5 $18,070 - $47,492	-785 Reduced 7.57%	9,582 $572,000
Q3 2017 Oct 24, 2017	SELL	$17.79 - $24.0 $3,308 - $4,464	-186 Reduced 1.76%	10,367 $249,000
Q2 2017 Aug 09, 2017	BUY	N/A	10,553	10,553 $206,000

146

140M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $157M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Leisure Capital Management, based on Form 13F filings with the SEC.

Stay updated on Leisure Capital Management with notifications on news.